These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25026813)

  • 1. [Cardiovascular diseases and osteoporosis: what is common?].
    Fedorchenko IL; Nebieridze DV; Safarian AS; Skripnikova IA; Sobchenko KE
    Ter Arkh; 2014; 86(5):116-9. PubMed ID: 25026813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
    Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
    Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.
    Lüscher TF; Spieker LE; Noll G; Cosentino F
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring vascular benefits of endothelium-derived nitric oxide.
    Cockcroft JR
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].
    Gel'tser BI; Kotel'niko v VN; Savchenko SV
    Ter Arkh; 2002; 74(12):34-7. PubMed ID: 12577837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T; Gori T
    J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
    Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
    J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
    Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
    J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
    Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
    Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL; Basile JN; Giles TD; Taylor AA
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-blockade: benefits beyond blood pressure reduction?
    Cockcroft JR; Pedersen ME
    J Clin Hypertens (Greenwich); 2012 Feb; 14(2):112-120. PubMed ID: 22277144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure.
    de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):56-60. PubMed ID: 17666916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of nebivolol on P wave duration and dispersion in patients with coronary slow flow.
    Güneş Y; Tuncer M; Güntekin U; Ceylan Y
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):290-5. PubMed ID: 19666430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease.
    Howlett JG
    Can J Cardiol; 2014 May; 30(5 Suppl):S29-37. PubMed ID: 24750980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.